ERBB2 and glioblastoma: Combination therapy of NK-92/5.28.z CAR-NK cells and anti-PD-1 checkpoint inhibition demonstrated robust anti-tumor activity and was able to selectively lyse HER2-expressing glioblastomas cells in vitro.